Brief: J&J Says Tremfya Meets Primary And Major Secondary Endpoints In Axial PsA Study

Johnson & Johnson

25/09/2026 12:44

Sept 25 (Reuters) - Johnson & Johnson JNJ.N:
JOHNSON & JOHNSON ANNOUNCES TREMFYA® (GUSELKUMAB) IS THE FIRST AND ONLY IL-23 INHIBITOR TO SHOW SIGNIFICANT IMPROVEMENT IN SPINAL PAIN AND STIFFNESS IN LANDMARK AXIAL PSORIATIC ARTHRITIS (PSA) STUDY
J&J - TREMFYA MEETS PRIMARY AND MAJOR SECONDARY ENDPOINTS IN AXIAL PSA STUDY
J&J - TREMFYA MEETS MAJOR SECONDARY ENDPOINTS FOR AXIAL SYMPTOMS AND MRI INFLAMMATION REDUCTION
J&J - STAR STUDY SHOWS TREMFYA SAFETY PROFILE CONSISTENT WITH PSA; NO NEW SAFETY SIGNALS
J&J - TREMFYA MEETS PRIMARY ENDPOINT FOR BASDAI SCORE IMPROVEMENT AT WEEK 24
Source text: ID:nPn67prhca
Further company coverage: JNJ.N

 ((Reuters.Briefs@thomsonreuters.com))